Clinical Utility of Fecal Calprotectin Monitoring in Asymptomatic Patients with Inflammatory Bowel Disease: A Systematic Review and Practical Guide

BÜHLMANN fCAL® ELISA:

Heidi A, Park KT, Rheenen PF. Clinical Utility of Fecal Calprotectin Monitoring in Asymptomatic Patients with Inflammatory Bowel Disease: A Systematic Review and Practical Guide. Inflamm Bowel Dis. 2017 Jun;23(6):894-902. doi: 10.1097/MIB.0000000000001082. PMID: 28511198

Highlights from this Publication

“This systematic review shows that the relapsing remitting nature of IBD becomes less unpredictable with proactive FC monitoring in clinical practice, allowing early recognition of relapse before overt symptoms (or symptom reporting).”

BÜHLMANN fCAL® ELISA is for Research Use Only.  Not for use in diagnostic procedures in the US.

Health Canada License: 80726

Share on FacebookShare on Google+Tweet about this on TwitterShare on LinkedInEmail this to someone